Mayne Pharma to acquire TherapeuticsMD's women's health portfolio

5 December 2022

Australia’s Mayne Pharma Group (ASX: MYX) has signed an exclusive license agreement with TherapeuticsMD (Nasdaq: TXMD) for three branded women’s health products and a portfolio of prenatal vitamins in the USA, with the news sending the US firm’s shares up 4.7% to $4.66 in pre-market trading.

Under the license agreement, Mayne will exclusively in-license Annovera (segesterone acetate/ethinyl estradiol), Imvexxy (segesterone acetate/ethinyl estradiol), Bijuva (estradiol and progesterone capsules) and the BocaGreenMD and vitaMedMD lines of prenatal vitamins and acquire selected assets including inventory and regulatory filings to support the operation and commercialisation of the portfolio.

The deal seems to represent the culmination TherapeuticsMD’s long search for a way out after a recent M&A proposal fell through. While EW Healthcare Partners had offered to pay $10 a share to buy out the biotech in a deal valued at $177 million, it did not acquire the required majority of shares of TherapeuticsMD through the previously announced tender offer by the extended offer deadline on July 12, 2022.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK